[Phase II study on oral administration of MCNU (ranomustine) tablet. Hanshin Cooperative Study Group on Hematological Disorders].
A phase II study of MCNU tablet has been performed on 70 patients with hematological disorders including mostly myeloproliferative disorders. MCNU tablet was given p.o. at a dose of 50 mg daily for 2-6 days (total 100-300mg) as one course with average intervals of 3 to 5 months or more for patients responding to this drug. The effective rates were 72% in 18 patients with chronic myelogenous leukemia, 88% in 25 patients with polycythemia vera and 68.5% in 19 patients with essential thrombocythemia. Side effects of MCNU tablet were nausea and vomiting (31%) which had a dose-dependent relationship, mild liver dysfunction (5%) and elevation of BUN and creatinine (2%) which were not serious. The results were almost comparable to those of the phase II study of MCNU given intravenously.
Kanamaru
A
A
Nagai
K
K
Masaoka
T
T
Shibata
H
H
Kitani
T
T
Taniguchi
N
N
Horiuchi
A
A
Tsubaki
K
K
Kawagoe
H
H
Hirata
M
M
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006402:Hematologic Diseases / Q000188:drug therapy*; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009607:Nitrosourea Compounds / Q000627:therapeutic use*; D011086:Polycythemia / Q000188:drug therapy; D013607:Tablets; D013922:Thrombocytosis / Q000188:drug therapy
D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; D013607:Tablets; C020766:ranimustine